



**Syngene**

Putting Science to Work

# Discovery Services

Innovate

Integrate

Customize

Accelerate

# 30 years of Putting Science to Work



## A Global CRO/CDMO

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small Molecules and Biologics, ADCs, Oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)



## Scientific Ecosystem

- 2 Mn sq. ft. world-class R&D and Manufacturing infrastructure
- 5200+ qualified scientists
- Ongoing \$510Mn (423.15 Mn Euro) investment program
- Highly effective supply chain practices



## IP Position

- IP assigned to clients
- Strong track record of Data Integrity and Security
- Over 400 patent assignments by clients recognizing Syngene



## Marquee Clients

- 400+ active clients last FY
- Partnering with large / mid-size / emerging BioPharma (EBP) and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors



## Quality Focus

- Quality driven organization
- Excellent track record of compliance with global regulators
- US FDA, EMA, ANVISA and PMDA approved, GLP Certified, Ministry of Health of Russian Federation, AAALAC & CAP accredited/certified facilities
- 15+ regulatory and 160+ client audits in the last 3 years



## Track Record

- Collaborations and partnerships to deliver numerous clinical candidates
- Delivery history for integrated CMC programs towards FIH and beyond

# Integrated Drug Discovery

Across multiple therapeutic areas and modalities to drive innovation and speed

## Therapeutic Areas

- Oncology
- Immunology
- Neuroscience
- Infectious diseases
- Cardiovascular and metabolism
- Inflammation
- Rare/orphan diseases

## Modalities

- Small molecules
- Peptides
- Oligonucleotides
- Antibodies
- Antibody drug conjugates
- PROTACs
- CAR-Ts

## Drug discovery at a global scale

1600

scientists, with  
95%+ Ms/Ph.D.

600,000

sq. ft. of  
lab space

200+

global  
clients

## Efficiency through co-localization of team members and capabilities

- IDD programs for 8 clients over 6 therapeutic areas
- Syngene-Synvent for therapeutic discovery on behalf of clients
- High rate of repeat business and return-clients



# Realize Your Next







## Drug candidate through our Chemistry, Biology, Safety/Tox and Computational and Data Sciences

- 95% on time delivery rate for known target compounds, >90% for unknown targets
- 25,000 reagents and 8,000 unique scaffolds in stock
- LCMS lab with ability to perform 96000 analyses/year and access to NMR lab to run 25000 samples/ year
- High-throughput mass based preparative HPLC lab for purifications with current capacity of 30000 compounds/year
- Completed ~40 PROTACs libraries (>98% success rate)
- 5000+ compounds in HT ADME assays / year
- 2500+ rodent (n=3) PK studies / year
- ADME studies turnaround in ~10 calendar days with >95% TAT adherence
- Computational and Data Sciences support across multiple stages of the discovery paradigm
- Effective use of CADD, cheminformatics and AI for multiparametric optimization




# Our Discovery Toolbox

We have the capabilities to apply the most appropriate modality for target validation and therapeutic discovery



# Our End-to-End Discovery Platform

Our end-to-end platform allows us to offer integrated as well as standalone services across the discovery continuum



We deliver our services (both Integrated & Functional) via a range of proven collaboration models



Dedicated R&D Labs




FTE




FFS

# Discovery Chemistry at Syngene

Discovery chemistry at Syngene is delivered by 900+ highly qualified scientists, backed by strong analytical chemistry support, robust IT infrastructure and ELN, as well as efficient data and compound management



**Integrated & collaborative drug discovery**  
Seamless co-ordination between Chemistry, Biology, DMPK and animal studies



**Analytical facilities supported by a team of 80 people**  
Strong IT support for ELN, data and compound management

# Discovery Biology at Syngene

The Discovery Biology team supports drug discovery across multi-modal platforms including small and large molecules as well as cell and gene therapy, across multiple therapy areas. Our diverse team of scientists solve complex biological problems in an integrated fashion, embracing scientific excellence, operational efficiency and commercial competitiveness.



**650+**  
scientists




**110,000**  
sq. ft lab space  
State of the art  
infrastructure



Protein  
Sciences



Cell  
Engineering



Antibody Discovery  
and engineering



Genomics and  
translational



Assay Biology  
& Screening



ADME DMPK



*In Vivo*  
Pharmacology



# Syngene Safety Assessment Services

Full range of *in vivo* and *in vitro* toxicology services for comprehensive non-clinical development of drugs

Exploratory studies	GLP studies	Phase I	Phase II	Phase III	Specialty studies
Pharmacokinetics	Analytical and bioanalytical studies to support safety tox program	Repeat dose studies & Genetic toxicology	Sub-chronic toxicity study		<i>In silico</i>
(MTD/Dose Escalation/Short-term repeat dose toxicology)	Repeat Dose Toxicology (2 Species)				Reproductive Toxicology (Male fertility/ Pre and Postnatal development)
Genotoxicity screening ( <i>in vitro</i> )	Genotoxicity ( <i>In vitro/ In vivo</i> )	Repeat dose studies & Genetic toxicology	Chronic Toxicology & Carcinogenicity		
Safety Pharmacology: CNS, Respiratory, CV	Toxicokinetics	Reproductive (Seg I-III) & Juvenile Toxicology			
	Core Battery Safety Pharmacology				
	Reproductive (Seg I-III) & Juvenile Toxicology				

# Computational and Data Sciences Capabilities

Syngene's Computational and Data Sciences capabilities enable informed decisions at all stages of the drug discovery continuum



Target  
Identification and  
Validation



Hit  
Identification




Hit to  
Lead



Lead  
Optimization



Candidate  
Selection





**Syngene**  
Putting Science to Work

## About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 5200+ scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter and Bristol-Myers Squibb, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA.

For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com) or write to us at [bdc@syngeneintl.com](mailto:bdc@syngeneintl.com)

© 2023 Syngene International Limited, All Rights Reserved.

Stay Connected

